Why is early fibrinogen replacement emphasized in obstetric hemorrhage?

Why is early fibrinogen replacement emphasized in obstetric hemorrhage?

• A. Pregnant patients have higher baseline fibrinogen, and a drop below 200 mg/dL is linked to severe PPH; early cryoprecipitate or fibrinogen concentrate helps prevent DIC.
• B. Fibrinogen levels are always low in pregnancy; replacement prevents anemia.
• C. Fibrinogen does not influence bleeding risk in obstetrics.
• D. Fibrinogen only matters after DIC develops.

Answer: (A)

In obstetric hemorrhage, fibrinogen is a key determinant of how well a clot forms and stays intact. Although pregnant women start with higher fibrinogen levels, during a severe bleed those levels can plummet quickly due to blood loss and dilution from IV fluids. When fibrinogen falls below about 200 mg/dL, the clot becomes weak and bleeding worsens, which is a strong indicator that the patient is at high risk for progressing to severe hemorrhage and disseminated intravascular coagulation. Replacing fibrinogen early—using cryoprecipitate or a fibrinogen concentrate—helps restore the clot’s strength before bleeding spirals out of control. This approach targets the underlying coagulopathy and supports hemostasis, rather than waiting for more obvious signs of trouble to appear. The other statements mischaracterize the situation: fibrinogen levels aren’t always low in pregnancy; the concern isn’t simply anemia, and fibrinogen directly influences bleeding risk in obstetrics. Waiting until DIC develops means treating a established crisis rather than preventing it.

In obstetric hemorrhage, fibrinogen is a key determinant of how well a clot forms and stays intact. Although pregnant women start with higher fibrinogen levels, during a severe bleed those levels can plummet quickly due to blood loss and dilution from IV fluids. When fibrinogen falls below about 200 mg/dL, the clot becomes weak and bleeding worsens, which is a strong indicator that the patient is at high risk for progressing to severe hemorrhage and disseminated intravascular coagulation.

Replacing fibrinogen early—using cryoprecipitate or a fibrinogen concentrate—helps restore the clot’s strength before bleeding spirals out of control. This approach targets the underlying coagulopathy and supports hemostasis, rather than waiting for more obvious signs of trouble to appear.

The other statements mischaracterize the situation: fibrinogen levels aren’t always low in pregnancy; the concern isn’t simply anemia, and fibrinogen directly influences bleeding risk in obstetrics. Waiting until DIC develops means treating a established crisis rather than preventing it.